Journal article
Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinoma.
- Abstract:
-
Cediranib is a highly potent and selective vascular endothelial growth factor (VEGF) signaling inhibitor with activity against all three VEGF receptors (VEGFRs) that inhibits angiogenesis and growth of human tumor xenografts in vivo. The present study evaluated the antitumor and antiangiogenic activity of cediranib in the clinically relevant, murine renal cell carcinoma (RENCA) model and its biological response using VEGF and sVEGFR-2 as biomarkers. Mice were treated with cediranib (5 mg/kg/d...
Expand abstract
- Publication status:
- Published
Actions
Authors
Bibliographic Details
- Journal:
- Anticancer research
- Volume:
- 29
- Issue:
- 12
- Pages:
- 5065-5076
- Publication date:
- 2009-12-01
- EISSN:
-
1791-7530
- ISSN:
-
0250-7005
- Source identifiers:
-
315723
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:315723
- UUID:
-
uuid:a7f007ef-1349-4738-8c76-9e4ce21be9af
- Local pid:
- pubs:315723
- Deposit date:
- 2013-11-17
Terms of use
- Copyright date:
- 2009
If you are the owner of this record, you can report an update to it here: Report update to this record